Pages that link to "Q40749012"
Jump to navigation
Jump to search
The following pages link to Prediction of hepatitis C burden in Canada (Q40749012):
Displaying 37 items.
- Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies (Q22305832) (← links)
- Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom (Q25256731) (← links)
- Burden of disease and cost of chronic hepatitis C infection in Canada (Q26849591) (← links)
- HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality (Q27488220) (← links)
- Global epidemiology of hepatitis C virus infection (Q27860799) (← links)
- Evolving epidemiology of hepatitis C virus (Q29619973) (← links)
- Health care costs associated with hepatitis C: a longitudinal cohort study (Q34417139) (← links)
- Mortality among British Columbians testing for hepatitis C antibody (Q34645221) (← links)
- Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). (Q35453012) (← links)
- Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection (Q35824825) (← links)
- Review article: the changing epidemiology of hepatocellular carcinoma in Canada (Q36166366) (← links)
- HIV and hepatitis C virus testing and seropositivity rates in Canadian federal penitentiaries: A critical opportunity for care and prevention (Q36170871) (← links)
- Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada (Q36272393) (← links)
- Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials (Q36398141) (← links)
- Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop (Q36655931) (← links)
- Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies (Q36761430) (← links)
- Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients (Q36883321) (← links)
- The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. (Q37144257) (← links)
- Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada (Q39692527) (← links)
- Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. (Q39965299) (← links)
- Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States (Q40249402) (← links)
- Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments (Q40396191) (← links)
- Pay Now or Pay (more) Later: Tracking the Costs of Hepatitis C Infection (Q42545888) (← links)
- Hepatitis C update. (Q43049017) (← links)
- Hepatitis C: the juggernaut rolls on unchecked (Q43153755) (← links)
- Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991-2006. (Q45072239) (← links)
- Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. (Q45383598) (← links)
- Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees (Q45731967) (← links)
- Cancer incidence in Canada: trends and projections (1983–2032). (Q46495297) (← links)
- Living with the stigma of hepatitis C. (Q50150025) (← links)
- An epidemiologic study of hepatocellular carcinoma in Canada. (Q50710892) (← links)
- Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model (Q50758340) (← links)
- Patient time costs and out-of-pocket costs in hepatitis C. (Q51175480) (← links)
- HIV and hepatitis C virus infections in Quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015 (Q59357500) (← links)
- Impact of availability of direct-acting antivirals for hepatitis C on Canadian hospitalization rates, 2012-2016 (Q64125370) (← links)
- Trends of hepatitis B and hepatitis C mortality in Canada, 1979-1997 (Q77967808) (← links)
- Canadian mortality rates for liver disease: taking a closer look at ICD coding (Q80188046) (← links)